Related Experiment Video
Updated: Aug 9, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Reprogramming of the tumour B-cell phenotype in Hodgkin lymphoma
Ralf Küppers1, Andreas Bräuninger
1Institute for Cell Biology (Tumor Research), University of Duisburg-Essen, Medical School, 45122 Essen, Germany. ralf.kuppers@uni-essen.de
Hodgkin and Reed-Sternberg (HRS) cells, the tumour cells in classical Hodgkin lymphoma, derive from mature B cells but have largely lost their B-cell phenotype. This extensive reprogramming is unique among B-cell lymphomas. A recent study by Dörken and colleagues provides an interesting insight into the mechanisms for this reprogramming by demonstrating that the key B-cell-determining transcription factor E2A is inhibited in HRS cells by the deregulated expression of its inhibitors activated B-cell factor (ABF)-1 and inhibitor of differentiation and DNA binding (Id)2.
Hodgkin and Reed-Sternberg (HRS) cells, the tumour cells in classical Hodgkin lymphoma, derive from mature B cells but have largely lost their B-cell phenotype. This extensive reprogramming is unique among B-cell lymphomas. A recent study by Dörken and colleagues provides an interesting insight into the mechanisms for this reprogramming by demonstrating that the key B-cell-determining transcription factor E2A is inhibited in HRS cells by the deregulated expression of its inhibitors activated B-cell factor (ABF)-1 and inhibitor of differentiation and DNA binding (Id)2.
Related Concept Videos
Somatic to iPS Cell Reprogramming
Methods of Nuclear Reprogramming
Introduction to Nuclear Reprogramming
Lineage Commitment

